Controversies regarding the use of dexamethasone in patients with multiple myeloma.
作者信息
Rajkumar S Vincent
机构信息
Mayo Clinic, Rochester, MN, USA.
出版信息
Clin Adv Hematol Oncol. 2008 Feb;6(2):103, 141.
PMID:18347560
Abstract
摘要
相似文献
1
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Clin Adv Hematol Oncol. 2008 Feb;6(2):103, 141.
2
Treatment of multiple myeloma: 2009 update.
Prescrire Int. 2009 Dec;18(104):263-6.
3
[New treatment strategies for multiple myeloma].
Rinsho Ketsueki. 2009 Oct;50(10):1506-17.
4
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5. Epub 2010 Dec 22.
5
Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
J Clin Oncol. 2006 Jan 20;24(3):334-6. doi: 10.1200/JCO.2005.03.8851. Epub 2005 Dec 19.
6
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Eur J Haematol. 2010 Dec;85(6):484-91. doi: 10.1111/j.1600-0609.2010.01526.x.
7
[Hematopoietic stem cell transplantation for multiple myeloma].
Rinsho Ketsueki. 2009 Oct;50(10):1420-6.
8
[Chemotherapy for multiple myeloma].
Nihon Rinsho. 2007 Dec;65(12):2280-4.
9
Novel agents in myeloma: an exciting saga.
Cancer. 2009 Jan 15;115(2):236-42. doi: 10.1002/cncr.24040.
10
First-line treatment of elderly multiple myeloma patients.
Clin Adv Hematol Oncol. 2010 Aug;8(8):529-30.
引用本文的文献
1
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma.
Br J Haematol. 2010 Mar;148(6):853-8. doi: 10.1111/j.1365-2141.2009.08023.x. Epub 2009 Dec 3.
Zotero 插件